July 1st 2025
A phase 2a trial shows tigilanol tiglate achieves an 80% response rate in soft tissue sarcoma, offering hope for effective treatment options.
Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
2nd Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer
View More
Experts Discuss the Spearhead 1 Trial and Other ASCO Data for Sarcoma Awareness Month
July 26th 2021During the 2021 American Society of Clinical Oncology Annual Meeting, multiple trials for targeted treatments were presented for soft tissue sarcoma. Dean Frohlich, PhD, and Brian A. Van Tine, MD, PhD, discuss the the results of some of these presentations, including the Spearhead 1 trial.
Read More
Precision Medicine Stakes Claim in the Gastrointestinal Stromal Tumors Landscape
March 9th 2021In an interview with Targeted Oncology, Margaret von Mehren, MD, reviews the recent advancements in the GIST treatment landscape. She also explains what’s needed to move the needle further in the future.
Read More
Adjuvant Imatinib Confirmed Beneficial for RFS in High-Risk Gastrointestinal Stromal Tumors
February 20th 2021Adjuvant imatinib has demonstrated significant improvement in relapse-free survival over a 2-year period and a mild trend toward long-term improvement in failure-free survival as treatment of patients with high-risk gastrointestinal stromal tumors, according to 9.1-year follow-up results from a randomized phase 3 study.
Read More
Invasive GIST Originating in the Stomach/Small Intestine Is More Common in Men, Study Shows
February 19th 2021Men appear to be more likely than women to have invasive gastrointestinal stromal tumors originating in the stomach and small intestines. For treatment, an expert says that combined surgery and systemic therapy demonstrates the best outcomes.
Read More
Expert Speaks to Impact of COVID-19 in the Community Oncology Setting, Vaccine Excites Field
December 16th 2020In an interview with Targeted Oncology, Michael J. Wagner, MD, discussed findings from a single-center experience in Seattle managing patients with sarcoma during the COVID-19 pandemic.
Read More
Novel Agent ADP-A2M4 Elicits Durable Response in Synovial Sarcoma
November 24th 2020The investigational engineered SPEAR T-cell agent, ADP-A2M4, induced durable responses in patients with synovial sarcoma, according to updated results from the phase 1 clinical trial presented during the Connective Tissue Oncology Society Annual Meeting.
Read More
Phase 1 Trial Exhibits Positive Interim Results in Chondrosarcoma
November 13th 2020Treatment with the investigation agent INBRX-109 induced responses and decreased the tumor burden in a cohort of patients with chondrosarcoma, according to interim efficacy and safety findings a phase 1 trial in patients with chondrosarcoma, Inhibrx, Inc announced in a press release.
Read More
Trabectedin Plus Durvalumab Feasible for Treatment of Soft Tissue Sarcoma
September 21st 2020Preliminary activity was observed in an unselected group of patients with miscellaneous soft tissue sarcoma treated with trabectedin in combination with durvalumab in the phase 1b TRAMUNE trial. The results presented during the 2020 European Society of Medical Oncology Virtual Congress demonstrate the feasibility of utilizing this combination in soft tissue sarcoma.
Read More
Pembrolizumab Extends Progression-Free Survival in Rare Sarcoma Subtypes
September 21st 2020Prolonged progression-free survival was observed with pembrolizumab monotherapy in patients with selected rare sarcoma subtypes treated in the phase 2 AcSé basket study, according to a presentation during the 2020 European Society of Medical Oncology Virtual Congress.
Read More
Ewing Sarcoma May Benefit From Regorafenib Therapy
September 20th 2020As compared with placebo, regorafenib induced favorable progression-free survival rates at 24 weeks versus placebo in patients with Ewing sarcoma in the phase 2 REGOBONE study. Despite this, the trial failed to meet its primary end point of non-progression at 8 weeks, according to findings presented at the European Society of Medical Oncology Virtual Congress 2020.
Read More